annb0t
Top 20
Clinuvel Pharmaceuticals (ASX:CUV) First Half 2023 Results
Key Financial Results
Revenue: AU$30.7m (up 25% from 1H 2022). Net income: AU$11.4m (up 94% from 1H 2022). Profit margin: 37% (up from 24% in 1H 2022). The increase in margin was driven by higher revenue. EPS: AU$0.23 (up from AU$0.12 in 1H 2022). earnings-and-revenue-growth
All figures shown in the chart above are for the trailing 12 month (TTM) period
Clinuvel Pharmaceuticals Earnings Insights
Looking ahead, revenue is forecast to...
>>> Read more: Clinuvel Pharmaceuticals First Half 2023 Earnings: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)
Key Financial Results
Revenue: AU$30.7m (up 25% from 1H 2022). Net income: AU$11.4m (up 94% from 1H 2022). Profit margin: 37% (up from 24% in 1H 2022). The increase in margin was driven by higher revenue. EPS: AU$0.23 (up from AU$0.12 in 1H 2022). earnings-and-revenue-growth
All figures shown in the chart above are for the trailing 12 month (TTM) period
Clinuvel Pharmaceuticals Earnings Insights
Looking ahead, revenue is forecast to...
>>> Read more: Clinuvel Pharmaceuticals First Half 2023 Earnings: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)
